- In June 2024, Gavi, the Vaccine Alliance, announced that lower-income countries can now apply to introduce four additional vaccines, a preventive Ebola vaccine, a human rabies vaccine for post-exposure prophylaxis, a multivalent meningococcal conjugate vaccine, and a hepatitis B birth dose. These programs, previously approved by the Gavi Board, were delayed due to the COVID-19 pandemic
- In July 2022, Arbutus Biopharma Corporation confirmed its continued dosing of patients in a Phase 2a clinical trial, evaluating its proprietary RNAi therapeutic in a triple combination treatment
- In July 2022, BioCyst Pharmaceuticals partnered with Pint Pharma GmbH to register and promote ORLADEYO (berotralstat) across the pan-India region, enhancing access to the treatment
- In October 2020, the U.S. FDA approved Inmazeb, the first treatment specifically for Ebola virus infection, developed by Regeneron Pharmaceuticals, the company also recognized for its antibody cocktail for COVID-19
- In July 2020, Johnson & Johnson secured European Commission approval for its Ebola vaccine regimen, allowing the company to collaborate with the WHO on vaccine pre-qualification, accelerating registration in African nations
